Two Sigma Advisers
IRD

Two Sigma Advisers’s Opus Genetics IRD Stock Holding History

Two Sigma Advisers’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,200
Closed -$16.8K – 2677
2025
Q3 		$16.8K Buy
+10,200
New +$12.7K ﹤0.01% 2307
2022
Q4 		– Sell
-18,200
Closed -$37K – 2729
2022
Q3 		$37K Sell
18,200
-134,200
-88% -$290K ﹤0.01% 2396
2022
Q2 		$293K Sell
152,400
-94,200
-38% -$214K ﹤0.01% 2131
2022
Q1 		$799K Sell
246,600
-71,500
-22% -$245K ﹤0.01% 1763
2021
Q4 		$1.19M Buy
318,100
+274,200
+625% +$1.1M ﹤0.01% 1472
2021
Q3 		$226K Buy
+43,900
New +$202K ﹤0.01% 2208

Other funds holding IRD

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Two Sigma Advisers's IRD Position: Q4 2025 in Review

Two Sigma Advisers sold out of Opus Genetics (IRD) in Q4 2025, closing a stake of 10,200 shares — an estimated $16.8K sold.

Two Sigma Advisers first reported a position in IRD in Q3 2021 and held it in 6 quarters. The position peaked at $1.19M in Q4 2021. 59 funds tracked by Wall St. Rank hold IRD as of Q4 2025.

  • Two Sigma Advisers reported no remaining Opus Genetics position as of Q4 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 10,200 Opus Genetics shares in Q4 2025, an estimated $16.8K.
  • Two Sigma Advisers first reported a position in Opus Genetics in Q3 2021 and held it in 6 quarters.
  • Two Sigma Advisers's Opus Genetics position peaked at $1.19M in Q4 2021.
  • 59 funds tracked by Wall St. Rank held Opus Genetics as of Q4 2025.

Based on Two Sigma Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.